Aortic valve replacement with the Cardioprotese Premium bovine pericardium bioprosthesis: four-year clinical results

Farias, Fabio Rocha; Costa, Francisco Diniz Affonso da; Filho, Eduardo Mendel Balbi; Fornazari, Daniele de Fátima; Collatusso, Claudinei; Ferreira, Andreia Dumsch de Aragon; Lopes, Sergio Veiga; Fernandes, Tadeu Augusto

doi:10.1093/icvts/ivs166

Cited by 4 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irrespective of whether pericardial‐made prostheses are manufactured as conventionally or minimally invasively implantable devices (Chacko et al, ; Farias et al, ; Johnston et al, ), they are “xenografts” whose integration in the host fail at mid‐long term for lack of a complete immunological compatibility and insufficient fixative detoxification. In fact, the treatment of animal tissues with aldehyde‐based fixatives leaves exogenous immunoreactive biological material (e.g., DNA), xenoantigens (e.g., the 1,3‐α‐Gal), and aldehyde residues, which determine a chronic rejection resulting in leaflet inflammation or calcification and progressive deterioration of mechanical performance (Carpentier, Lemaigre, Robert, Carpentier, & Dubost, ; Grabenwoger et al, ; Schoen & Levy, ; Siddiqui, Abraham, & Butany, ).…”

Section: Introductionmentioning

confidence: 99%

Aortic valve cell seeding into decellularized animal pericardium by perfusion-assisted bioreactor

Amadeo

Boschetti

Polvani

et al. 2018

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Animal-derived pericardium is the elective tissue employed in manufacturing heart valve prostheses. The preparation of this tissue for biological valve production consists of fixation with aldehydes, which reduces, but not eliminates, the xenoantigens and the donor cellular material. As a consequence, especially in patients below 65-70 years of age, the employment of valve substitutes contaning pericardium is not indicated due to progressive calcification that causes tissue degeneration and recurrence of valve insufficiency. Decellularization with ionic or nonionic detergents has been proposed as an alternative procedure to prepare aldehyde- or xenoantigen-free pericardium for biological valve manufacturing. In the present contribution, we optimized a decellularization procedure that is permissive for seeding and culturing valve competent cells able to colonize and reconstitute a valve-like tissue. A high-efficiency cellularization was achieved by forcing cell penetration inside the pericardium matrix using a perfusion bioreactor. Because the decellularization procedure was found not to alter the collagen composition of the pericardial matrix and cells seeded in the tissue constructs consistently grew and acquired the phenotype of "quiescent" valve interstitial cells, our investigation sets a novel standard in pericardium application for tissue engineering of "living" valve implants.

show abstract

Section: Introductionmentioning

confidence: 99%

Aortic valve cell seeding into decellularized animal pericardium by perfusion-assisted bioreactor

Amadeo

Boschetti

Polvani

et al. 2018

J Tissue Eng Regen Med

View full text Add to dashboard Cite

show abstract

“…In-hospital mortality was 8.16%, compared to national reports of 8% [ 13 ] mortality for general cardiac surgery and from 7.0 to 15.0% for aortic valve replacement [ 14 , 15 ] , not adjusted. Being a tertiary center with great experience in bioprosthesis implantation [ 6 , 7 ] and in reoperations [ 16 , 17 ] , there is a high incidence of previous cardiac surgeries, historically rising - from 1980 to 1999, 22.8% were reoperations [ 16 ] and, from 2006 to 2010, 27.5% were reoperations.…”

Section: Discussionmentioning

confidence: 78%

Late outcome analysis of the Braile Biomédica® pericardial valve in the aortic position

Azeredo¹,

Veronese²,

Santiago³

et al. 2014

Revista Brasileira De Cirurgia Cardiovascular

View full text Add to dashboard Cite

ObjectiveAortic valve replacement with Braile bovine pericardial prosthesis has been routinely done at the Heart Institute of the Universidade de São Paulo Medical School since 2006. The objective of this study is to analyze the results of Braile Biomédica® aortic bioprosthesis in patients with aortic valve disease.MethodsWe retrospectively evaluated 196 patients with aortic valve disease submitted to aortic valve replacement with Braile Biomédica® bovine pericardial prosthesis, between 2006 and 2010. Mean age was 59.41±16.34 years and 67.3% were male. Before surgery, 73.4% of patients were in NYHA functional class III or IV.ResultsHospital mortality was 8.16% (16 patients). Linearized rates of mortality, endocarditis, reintervention, and structural dysfunction were 1.065%, 0.91%, 0.68% and 0.075% patients/year, respectively. Actuarial survival was 90.59±2.56% in 88 months. Freedom from reintervention, endocarditis and structural dysfunction was respectively 91.38±2.79%, 89.84±2.92% and 98.57±0.72% in 88 months.ConclusionThe Braile Biomédica® pericardial aortic valve prosthesis demonstrated actuarial survival and durability similar to that described in the literature, but further follow up is required to assess the incidence of prosthetic valve endocarditis and structural dysfunction in the future.

show abstract

“…The structure of the biological prosthesis is similar to the natural and the mechanical valve made of alloys and synthetic materials [2]. Bioprosthesis are characterized by a good hemodynamic parameters [3,4,5,6] but their stability is not sufficient [7] so there is a need to construct a functional bioprosthesis resistant to phenomenon called calcification and degeneration of the leaflets. Each bioprosthesis model must be tested for its biocompatibility, functionality and durability -strength and fatigue resistance [8].…”

Section: Introductionmentioning

confidence: 99%

Comparative in Vitro Research of the Human Aortic Bioprosthesis

Dawidowska

2014

Advances in Materials Science

View full text Add to dashboard Cite

Evaluate of the usefulness and reliability of structures based on the analysis of recorded parameters determining the flow through the Human Aortic Bioprosthesis (HAB) have been dealt with. By flow parameters changes determining the performance environment of prosthesis analyzed change of the motion dynamics of the valve leaflets as a function of pressure, thereby determining the degree of alignment of the prosthesis to the performance conditions. Based on the gathered measurement data a comparative analysis of flow rate valve prostheses for different frequency values of the piston pump imitating the heart, different ejection capacity and pressure conditioning work environment prosthesis were studied. Interpretation of the recorded image gave the basis for determining the Effective Orifice Area (EOC).

show abstract

Aortic valve replacement with the Cardioprotese Premium bovine pericardium bioprosthesis: four-year clinical results

Abstract: The Premium bioprosthetic aortic valve demonstrated very satisfactory clinical and echocardiographic results up to 4 years, similar to other commercially available, third-generation bioprosthetic valves.

Cited by 4 publications

References 14 publications

Aortic valve cell seeding into decellularized animal pericardium by perfusion-assisted bioreactor

Aortic valve cell seeding into decellularized animal pericardium by perfusion-assisted bioreactor

Late outcome analysis of the Braile Biomédica® pericardial valve in the aortic position

Comparative in Vitro Research of the Human Aortic Bioprosthesis

Contact Info

Product

Resources

About